Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-Extension study)
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Over recent years, research on anticoagulant drugs has been guided by the requirement for convenient administration and a wide therapeutic window to allow fixed dosing without the need for coagulation monitoring. Rivaroxaban is the first of a new class of anticoagulant drugs, the direct, selective inhibitors of Factor Xa. The EINSTEIN-extension study compared rivaroxaban with placebo in patients who completed their standard treatment course after venous thromboembolism (VTE), in whom there was equipoise with respect to the need for continued anticoagulation. After 6-12 months of treatment, rivaroxaban significantly reduced the risk of recurrent VTE at the cost of a moderate increase in bleeding complications. Overall, these results suggest that rivaroxaban can be a valid alternative to warfarin for patients requiring long-term secondary prevention of VTE. However, additional data are needed for special populations including the elderly, patients with cancer, renally impaired patients and morbidly obese patients, all of whom were scarcely represented in this trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Prandoni, P., Noventa, F., Ghirarduzzi, A., Pengo, V., Bernardi, E., Pesavento, R., Iotti, M., Tormene, D., Simioni, P., & Pagnan, A. (2007) · Haematologica · doi:10.3324/haematol.10516 · Cited by 776
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
Agnelli, G., Prandoni, P., Santamaria, M. G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450302 · Cited by 591
Self-citationIorio, A., Kearon, C., Filippucci, E., Marcucci, M., Macura, A., Pengo, V., Siragusa, S., & Palareti, G. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.367 · Cited by 385
Buller, H. R., Lensing, A. W. A., Prins, M. H., Agnelli, G., Cohen, A., Gallus, A. S., Misselwitz, F., Raskob, G., Schellong, S., & Segers, A. (2008) · Blood · doi:10.1182/blood-2008-05-160143 · Cited by 342
Agnelli, G., Gallus, A., Goldhaber, S. Z., Haas, S., Huisman, M. V., Hull, R. D., Kakkar, A. K., Misselwitz, F., & Schellong, S. (2007) · Circulation · doi:10.1161/circulationaha.106.668020 · Cited by 337
Cited by
Ensor, J., Riley, R. D., Moore, D., Snell, K. I. E., Bayliss, S., & Fitzmaurice, D. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011190 · Cited by 84
Preblick, R., Kwong, W. J., White, R. H., & Goldhaber, S. Z. (2015) · Hospital Practice · doi:10.1080/21548331.2015.1099412 · Cited by 28
“Because VTE patients have a long-term risk of recurrence, treatment beyond 1-year and in some cases lifelong is warranted.[30] Our study is limited to model duration of 1 year due to data”
BackgroundRollins, B. M., Silva, M. A., Donovan, J. L., & Kanaan, A. O. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.033 · Cited by 18
Metadata
- Authors
- Romualdi, E., Donadini, M. P., & Ageno, W.
- Venue
- Expert Review of Cardiovascular Therapy
- Publisher
- Informa UK Limited
- Published
- 2011-07
- Volume
- 9
- Issue
- 7
- Pages
- 841-844
- ISSN
- 1477-9072 (ISSN-L)
- 1744-8344
- OpenAlex
- W2117966469
- Cited by
- 129
- References
- 6
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.